BioMarin Pharmaceuticals
BMRN
539 hedge funds and large institutions have $11.2B invested in BioMarin Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 168 increasing their positions, 211 reducing their positions, and 127 closing their positions.
69% more call options, than puts
Call options by funds: $120M | Put options by funds: $70.8M
15% more capital invested
Capital invested by funds: $9.72B → $11.2B (+$1.46B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4.47% more ownership
Funds ownership: 93.49% → 97.96% (+4.5%)
7% less funds holding
Funds holding: 577 → 539 (-38)
20% less repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 211
20% less first-time investments, than exits
New positions opened: 101 | Existing positions closed: 127
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$124M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$118M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.6M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$64M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$58.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$158M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$124M |
| 3 |
Goldman Sachs
New York
|
-$100M |
| 4 |
State Street
Boston,
Massachusetts
|
-$67.6M |
| 5 |
Man Group
London,
United Kingdom
|
-$61.6M |
BMRN Hedge Fund Activity: Q4 2025 in Review
539 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2025, worth a combined $11.2B — up 15% from $9.72B a quarter earlier.
Sellers outnumbered buyers: 127 funds closed out of BMRN and 101 opened new positions — a net loss of 26 holders — while 211 trimmed existing stakes and 168 added.
The largest buyer was Deep Track Capital, adding an estimated $124M. The largest seller was BlackRock, cutting an estimated $158M.
- 539 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2025, down from 577 in Q3 2025.
- Funds reported $11.2B of BioMarin Pharmaceuticals stock for Q4 2025, up 15% quarter-over-quarter.
- 101 funds opened new BioMarin Pharmaceuticals positions in Q4 2025 and 127 closed out, a net change of -26 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2025 was Deep Track Capital, an estimated $124M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2025 was BlackRock, an estimated $158M sold.
Based on aggregated 13F filings for Q4 2025.